Connect with us

Company News

Cipla Receives Final Approval for Generic Version of Roche’s Valcyte

Cipla Limited announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Valganciclovir Tablets 450 mg from the United States Food and Drug Administration (US FDA). Cipla’s Valganciclovir Tablets 450 mg is AB-rated generic therapeutic equivalent version of Roche’s Valcyte. It is a deoxynucleoside analogue cytomegalovirus (CMV) DNA polymerase inhibitor indicated for use in the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS) and prevention of CMV disease in kidney, heart, and kidneypancreas transplant patients at high risk. According to IQVIA (IMS Health), Valcyte and its generic equivalents had US sales of approximately USD 79 million for the 12-month period ending September 2018. The product is available for shipping immediately. – Medical Buyer Bureau

Copyright © 2024 Medical Buyer

error: Content is protected !!